Deals in Depth: August 2012

GSK sold to Aspen Global a group of products in Australia for $270 million. PE firm Cinven paid $730 million for branded and generics company Mercury Pharma. Debt offerings overwhelmingly were the most popular method of financing in both biopharma and device industries.